A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

Omura, George; Major, Francis J.; Blessing, John A.; Sedlacek, Thomas V.; Thigpen, J.T.; Creasman, William T.; Zaino, Richard J.

doi:10.1002/1097-0142(19830815)52:4<626::aid-cncr2820520409>3.0.co;2-e

Cited by 335 publications

(136 citation statements)

References 12 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…Negligible activity was observed in phase II trials testing the following drugs as single agents: cisplatin, mitoxantrone, amonifide, oral etoposide, diazoquone (AZQ), intravenous etoposide, topotecan, paclitaxel, thalidomide, and trimetrexate [3][4][5][6][7][8][9][10][11][12][13][14]. Single agents that show moderate activity in leiomyosarcoma include ifosfamide (response rate 17.2%), doxorubicin (response rate 25%), and gemcitabine (bolus infusion achieved a 20% response rate among women with uterine leiomyosarcoma who had received 0-1 prior cytotoxic regimen) [15][16][17]. Trabectedin achieved a response rate of 8% among patients with prior treatment, and 17% as first-line therapy, in patients with soft tissue sarcoma [18][19].…”

Section: Introductionmentioning

confidence: 99%

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

Hensley

Blessing

Mannel

et al. 2008

Gynecologic Oncology

246

133

View full text Add to dashboard Cite

Objective-Doxorubicin-based treatment is standard therapy for metastatic uterine leiomyosarcoma. There is no standard second-line therapy. We determined activity of fixed-dose rate gemcitabine plus docetaxel as second-line treatment for metastatic uterine leiomyosarcoma.Methods-Eligible women with unresectable uterine leiomyosarcoma progressing after prior cytotoxic therapy were treated with gemcitabine 900 mg/m 2 days one and eight over 90 minutes, plus docetaxel 100 mg/m 2 on day 8 of a 21-day cycle with granulocyte growth factor. Patients with prior pelvic radiation received lower doses. Response Evaluation Criteria in Solid Tumors (RECIST) response was assessed by computed tomography (CT).Results-Forty-eight of 51 women were evaluable for response (one wrong histology, two never treated). Prior therapy was doxorubicin-based in 90%, and ifosfamide-based in 6%. The overall objective response rate is 27%, with complete response in 6.3% (3/48), and partial response in 20.8% (10/48). An additional 50% (24/48) had stable disease (median duration 5.4 months). The median number of cycles per patient was 5.5 (range 1-22); 73% of patients remained progression-free at 12 weeks and 52% at 24 weeks. The predominant toxicity was uncomplicated myelosuppression: thrombocytopenia grade 3 (29%), grade 4 (10.4%); neutropenia grade 3 (12.5%), grade 4 (8.3%) anemia grade 3 (20.8%), grade 4 (4.2%). While pulmonary toxicity was reported, no patient had drug-related pneumonitis/hypoxia-type toxicity. Median progression-free survival (PFS) was 5. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public Access NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript months (range 0.7 -27+ months). The median duration of objective response was 9+ months (range 3.9 -24.5+ months).Conclusion-Fixed-dose rate gemcitabine plus docetaxel is active second-line therapy for uterine leiomyosarcoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

Hensley

Blessing

Mannel

et al. 2008

Gynecologic Oncology

246

133

View full text Add to dashboard Cite

show abstract

“…Omura et al (9) investigated the efficiency of ADM + DTIC therapy and reported that, among 66 cases with measurable lesions of uterine sarcoma, 16 (24.2%) achieved a remission (CR + PR). Specifically, the response rate was 30.0% (6/20) in cases with LMS.…”

Section: Discussionmentioning

confidence: 64%

A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma

Yamagami

Susumu

Ninomiya

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. There is currently insufficient evidence to recommend a specific chemotherapeutic regimen as standard treatment for uterine sarcomas. In this study, we investigated the toxicity and effectiveness of ifosfamide, adriamycin and cisplatin (IAP therapy) in patients with progressive and recurrent uterine sarcoma. A total of 11 patients with progressive or recurrent uterine sarcoma containing leiomyosarcoma (LMS), undifferentiated endometrial sarcoma (UES) or adenosarcoma, who were diagnosed at our institution, were retrospectively investigated. We recorded the adverse events, response rate and progression-free survival in these cases. The histological types included LMS (54.5%), adenosarcoma (27.3%) and UES (18.2%). Grade ≥3 leukopenia or neutropenia were observed in all the cases, febrile neutropenia developed in 45.5% of the patients and grade 4 thrombocytopenia developed in 3 cases (27.3%). With IAP therapy, the response rate was 36.4% and the disease control rate was 90.9%. Therefore, IAP therapy may be a viable option as chemotherapy for uterine sarcoma.

show abstract

“…Rational therapeutic regimens for metastatic soft-tissue sarcomas have not been established. ADR is the most effective single agent, with a response of 16-27% for treatment of soft-tissue sarcomas [6][7][8].…”

Section: Discussionmentioning

confidence: 99%

“…Large randomized studies, comparing ADR-based combination chemotherapy regimens with single-agent ADR, have been reported. In some of these trials response was greater in the combination chemotherapy arms [6][7][8] whereas in others primary outcomes were not significantly different between treatments. MAID, which we chose in this case, is a recommended combination regimen for softtissue sarcoma according to the National Comprehensive Cancer Network guidelines [9].…”

Section: Discussionmentioning

confidence: 99%

Metastatic myxofibrosarcoma of the spermatic cord responding to mesna, adriamycin, ifosfamide, and dacarbazine combination therapy

et al. 2012

View full text Add to dashboard Cite

Myxofibrosarcoma is common in the extremities of elderly people and is characterized by a high frequency of local recurrence. We report herein a case of a 72-year-old male who presented with a 5-year history of right scrotal swelling and a month history of painful swelling in the scrotal area. Computed tomography scan revealed a scrotal tumor 5 cm in size and a tumor in the rectum. He subsequently underwent right high orchiectomy and rectal dissection with colostomy. The scrotal tumor was histopathologically diagnosed as a myxofibrosarcoma; the rectal tumor was a leiomyosarcoma. The patient underwent tumor resection for recurrence and left inguinal metastasis, but soon developed local recurrences and lymph node metastasis of the left iliac area. Chemotherapy with mesna, adriamycin, ifosfamide, and dacarbazine (MAID) resulted in partial remission. We report the rare case of myxofibrosarcoma in the spermatic cord for which chemotherapy with MAID was an effective treatment.

show abstract

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

Cited by 335 publications

References 12 publications

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma

Metastatic myxofibrosarcoma of the spermatic cord responding to mesna, adriamycin, ifosfamide, and dacarbazine combination therapy

Contact Info

Product

Resources

About